Wyeth Set To File NDA For Antipsychotic Bifeprunox In 2006
This article was originally published in The Pink Sheet Daily
Executive Summary
Wyeth has partnered with Solvay to structure a development plan for the atypical antipsychotic.
You may also be interested in...
Wyeth Says Bifeprunox Side Effect Profile Is Benefit Over Atypical Antipsychotics
NDA submission buoyed by four Phase III studies, including two involving active comparators.
Wyeth Says Bifeprunox Side Effect Profile Is Benefit Over Atypical Antipsychotics
NDA submission buoyed by four Phase III studies, including two involving active comparators.
Antipsychotic Drug Stabilization Period For Long-Term Studies Can Be Short, Vanda Pharma Says
Patient response periods in past studies have been as short as one month, the antipsychotic drug developer maintains in briefing materials for Oct. 25 meeting of psychopharmacologic advisory committee.